r 428

Bemcentinib (R428) belongs to small molecule inhibitors and is a highly selective oral Axl inhibitor (IC50 = 14 nM) with oral bioavailability and potent cell permeability. This compound effectively inhibits cancer cell migration and invasion, blocks tumor dissemination, and prolongs survival in various tumor models.

Bemcentinib-d8 (R428-d8) is the deuterium-labeled form of Bemcentinib. Bemcentinib (R428) is an orally active, selective Axl inhibitor with an IC50 of 14 nM. It inhibits cancer cell migration and invasion. In cells, its selectivity for Axl is over 100-fold greater than for Abl, and over 50- and 100-fold greater for the TAM family kinases Mer and Tyro3, respectively. Bemcentinib can prevent tumor spread in metastatic breast cancer models and extends survival.

(R)-Bemcentinib ((R)-R428) is the R-enantiomer of Bemcentinib. Known as a selective, orally active Axl inhibitor, Bemcentinib (R428) has an IC50 value of 14 nM. This compound can impede tumor spread and improve survival in models of metastatic breast cancer.

Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is a humanized monoclonal antibody targeting Lysosomal-Associated Membrane Protein 1 (LAMP1/CD107a). LAMP1 is typically located on lysosomal membranes but is highly expressed on the surface of various solid tumor cells. Serving as the targeting moiety of the antibody-drug conjugate (ADC) SAR-428926, this antibody specifically binds to surface-expressed LAMP1, mediating the internalization of the ADC and the release of a potent maytansinoid cytotoxic payload. This targeting strategy demonstrates outstanding anti-tumor efficacy in patient-derived xenograft (PDX) models of solid tumors, effectively inhibiting tumor growth.